St Bernards Medical Center
- Type
- Teaching hospital
- Where
- JONESBORO, AR
- Medicare CCN
- 040020
- Received
- $712,056 in 49 records, 2021 ($2,569 general, $709,486 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: ST BERNARDS MEDICAL CENTER Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 2 | $2,569 |
| 2021 | Research payment | 47 | $709,486 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | 1 | $273,732 | 2021 |
| Merck Sharp & Dohme LLC | 4 | $222,921 | 2021 |
| Amgen Inc. | 4 | $98,941 | 2021 |
| Boston Scientific Corporation | 15 | $49,614 | 2021 |
| Eli Lilly and Company | 5 | $31,955 | 2021 |
| PFIZER INC. | 4 | $14,855 | 2021 |
| SEAGEN INC. | 4 | $8,000 | 2021 |
| Endologix LLC | 1 | $4,062 | 2021 |
| Celgene Corporation | 1 | $3,860 | 2021 |
| Medline Industries LP | 2 | $2,569 | 2021 |
| Pharmacyclics LLC, an AbbVie Company | 7 | $1,050 | 2021 |
| Incyte Corporation | 1 | $494 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 47 | $709,486 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 2 | $2,569 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Merck Sharp & Dohme LLC | $119,367 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $71,661 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab ver | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $21,891 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab ver | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $10,000 | Research payment | In-kind items and services | Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab | 2021 |
| 2021-12-16 | SEAGEN INC. | $2,000 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-12-15 | Endologix LLC | $4,062 | Research payment | Cash or cash equivalent | Detour II Study | 2021 | |
| 2021-12-14 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-12-06 | Boston Scientific Corporation | $2,063 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | ELEGANCE | 2021 |
| 2021-12-06 | Boston Scientific Corporation | $1,338 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | SAVAL PIVOTAL | 2021 |
| 2021-11-23 | PFIZER INC. | $2,119 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2021 | |
| 2021-11-05 | PFIZER INC. | $331 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2021 | |
| 2021-11-01 | Boston Scientific Corporation | $7,101 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | ELEGANCE | 2021 |
| 2021-11-01 | Boston Scientific Corporation | $1,702 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | SAVAL PIVOTAL | 2021 |
| 2021-10-08 | PFIZER INC. | $2,205 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2021 | |
| 2021-10-04 | Boston Scientific Corporation | $7,283 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | ELEGANCE | 2021 |
| 2021-10-04 | Boston Scientific Corporation | $248 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | SAVAL PIVOTAL | 2021 |
| 2021-09-08 | Eli Lilly and Company | $480 | Research payment | In-kind items and services | EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE | 2021 | |
| 2021-09-07 | Boston Scientific Corporation | $4,408 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | SAVAL PIVOTAL | 2021 |
| 2021-09-07 | Boston Scientific Corporation | $2,317 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | ELEGANCE | 2021 |
| 2021-08-03 | Boston Scientific Corporation | $4,014 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | ELEGANCE | 2021 |
| 2021-07-26 | SEAGEN INC. | $2,000 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-07-06 | Boston Scientific Corporation | $876 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | ELEGANCE | 2021 |
| 2021-06-07 | Boston Scientific Corporation | $8,259 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | SAVAL PIVOTAL | 2021 |
| 2021-05-18 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-05-18 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-05-04 | Boston Scientific Corporation | $3,817 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | SAVAL PIVOTAL | 2021 |
| 2021-05-01 | PFIZER INC. | $10,200 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A | 2021 |
| 2021-04-26 | Eli Lilly and Company | $733 | Research payment | In-kind items and services | A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CAN | 2021 | |
| 2021-04-24 | Amgen Inc. | $11,820 | Research payment | Cash or cash equivalent | Nplate Biological, Hematology | LCM:A Phase 3 Randomized Placebo Controlled Study of the Treatment of CIT for Solid Tumors- Study 1 | 2021 |
| 2021-04-19 | Medline Industries LP | $1,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Biosense Webster EP Mapping Sensor Device, Reprocessing | 2021 | |
| 2021-03-28 | Amgen Inc. | $275 | Research payment | In-kind items and services | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC. | 2021 |
| 2021-03-25 | SEAGEN INC. | $2,000 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-03-15 | Boston Scientific Corporation | $1,660 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | SAVAL PIVOTAL | 2021 |
| 2021-02-26 | Medline Industries LP | $1,269 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | St. Jude Medical EP Catheters Device, Reprocessing | 2021 | |
| 2021-02-15 | Boston Scientific Corporation | $2,687 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | SAVAL PIVOTAL | 2021 |
| 2021-02-10 | Celgene Corporation | $3,860 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology | Connect MDS/AML | 2021 |
| 2021-02-08 | Amgen Inc. | $57,474 | Research payment | In-kind items and services | Nplate Biological, Hematology | LCM:A Phase 3 Randomized Placebo Controlled Study of the Treatment of CIT for Solid Tumors- Study 1 | 2021 |
| 2021-02-08 | Amgen Inc. | $29,372 | Research payment | In-kind items and services | Nplate Biological, Hematology | LCM: A Phase 3 Randomized Placebo Controlled Study of the Treatment of CIT for Solid Tumors- Study 2 | 2021 |
| 2021-02-02 | Eli Lilly and Company | $7,029 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD | 2021 | |
| 2021-01-26 | Eli Lilly and Company | $23,624 | Research payment | Cash or cash equivalent | A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CAN | 2021 | |
| 2021-01-26 | Eli Lilly and Company | $87 | Research payment | In-kind items and services | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD | 2021 | |
| 2021-01-25 | SEAGEN INC. | $2,000 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-01-20 | Incyte Corporation | $494 | Research payment | Cash or cash equivalent | PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED | 2021 | |
| 2021-01-19 | Novartis Pharmaceuticals Corporation | $273,732 | Research payment | Cash or cash equivalent | KISQALI Drug, ONCOLOGY | RIBOCICLIB STANDARD ENDOCRINE THERAPY IN PATIENTS WITH HR HER2 EARLY BC AT HIGH AMP INTERMEDIATE RISK FOR RECURRENCE | 2021 |
| 2021-01-19 | Boston Scientific Corporation | $1,835 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | SAVAL PIVOTAL | 2021 |
| 2021-01-14 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-01-14 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-01-14 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-01-14 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Jonesboro, AR, county Craighead County, AR, state Arkansas; placed by its city name.
| Measure | Place (city or town) Jonesboro, AR | County Craighead County, AR | State Arkansas |
|---|---|---|---|
| Population B01003 | 80,137 | 113,249 | 3,049,391 |
| Population, 2020 census P1 | 78,576 | 111,231 | 3,011,524 |
| Median age B01002 | 33.9 | 34.5 | 38.5 |
| Under 18 B01001 | 24.0% | 25.2% | 23.1% |
| 65 and over B01001 | 14.2% | 13.9% | 17.6% |
| Households B11001 | 31,913 | 44,437 | 1,205,987 |
| Foreign born B05002 | 4.6% | 3.7% | 5.4% |
| Median household income B19013 | $55,424 | $59,548 | $60,773 |
| Median family income B19113 | $72,057 | $75,703 | $76,968 |
| Per capita income B19301 | $33,544 | $33,774 | $34,225 |
| Poverty rate B17001 | 22.8% | 20.1% | 16.0% |
| Unemployment rate B23025 | 6.3% | 5.6% | 4.9% |
| Civilian labor force B23025 | 38,912 | 55,535 | 1,411,269 |
| Mean commute (minutes) B08013 | 18.0 | 19.6 | 22.5 |
| Bachelor's degree or higher B15003 | 31.8% | 29.7% | 25.7% |
| Housing units B25001 | 35,002 | 48,885 | 1,394,673 |
| Owner-occupied B25003 | 54.3% | 60.1% | 66.4% |
| Renters B25003 | 45.7% | 39.9% | 33.6% |
| Median home value B25077 | $223,200 | $210,400 | $188,000 |
| Median gross rent B25064 | $956 | $958 | $947 |
| White, not Hispanic B03002 | 63.0% | 70.8% | 67.4% |
| Black B03002 | 22.7% | 16.6% | 14.6% |
| Hispanic or Latino B03002 | 7.5% | 6.3% | 9.0% |
| Asian B03002 | 1.6% | 1.2% | 1.6% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 3.9% in Sep 2026 (4.2% a year earlier); per capita personal income $61,697 in 2025, up 31% in five years (+5.2% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Jonesboro, AR.
Comments